The Quantum Newsroom
Evidence, in the open.
From protocol to site list, on one evidence base
A sponsor’s world-class experts could agree on the science, but not on the number the whole program hinged on: how many patients would actually qualify? We could answer it — and the final protocol qualified nearly three times the patients of the draft, then became a ranked list of the sites that can actually reach them.
They guess. We count.
Most site-selection tools infer where patients probably are from a partial sample. We count the actual patients, across every institution — and why that difference decides a rare-disease trial.
Read →Real-world data for clinical trials, explained
What it is, how CROs use it for feasibility and site selection, and why licensing data and getting answers are not the same thing.
Read the guide →Choosing rare disease trial sites: the questions to ask
21 questions, from how many patients each site really treats to which famous centers should not be on the list.
Read the guide →Latest — Quantum Research launches the AI Founding Partner Program →
Media enquiries: marketing@quantumresearch.cloud
Nothing in this section yet — more is on the way.
They guess. We count.
Let’s talk about your study.
We will show you the qualifying patients and the investigators who will enroll them — the evidence you walk into the bid defense with.